Why we study brain cancer
The most common and aggressive form of adult brain cancer termed glioblastoma (GBM) kills approximately 1200 people per year in Australia. GBM survival is very poor with a median survival of approximately 15 months. Unfortunately, meaningful increases in patient treatment and survival have not changed for decades. New and better therapies to treat these aggressive diseases are urgently needed.
Our laboratory also studies a number of paediatric brain cancers including medulloblastoma and a highly incurable but rare form of brain stem glioma termed diffuse intrinsic pontine glioma (DIPG). Our focus is to define receptors that are only present on children’s brain tumours and not on normal brain. Our goal is to design therapies to target these tumour-specific receptors enabling us to specifically target the tumour while keeping normal healthy developing brain intact.
- Professor Bryan Day, Group Leader and Sid Faithfull Fellow
- Professor Andrew Boyd, Honorary Scientist
- Dr Carolin Offenhauser, Postdoctoral Scientist
- Dr Seçkin Akgül, Postdoctoral Scientist
- Dr Rochelle D’Souza, Postdoctoral Scientist
- Fiona Smith, Research Assistant
- Manasi Jiwrajka, MPhil Student
- Michelle Li, PhD Student
- Courtney Jurd, Administration Officer
- Soonjung Lee, Honours Student
- Defining Eph receptors as therapeutic targets in brain cancer
- Defining novel therapies for the treatment of brain cancer
- Understanding intratumoural heterogeneity and interclonal cooperativity in brain cancer
- Brain cancer tissue and culture bank development
Sid Faithfull and Christine Sadler
Sid Faithfull and his wife, Christine Sadler, have been major supporters of QIMR Berghofer since 2013. Tragically, Sid passed away from brain cancer in 2014. In June 2018 our lab was renamed as the Sid Faithfull Brain Cancer Laboratory to honour Sid and the valuable contributions of his family. Christine and Sid’s visionary investment enables us to build capacity through innovation, obtain vital resources and instigate trials that ultimately lead to better treatments and improved quality of life for people suffering brain cancer.
Sid grew up in the Far North of Australia and experienced a wide range of interesting professions before finding his niche in maritime logistical support. A visionary in many ways, Sid realised opportunities and had the courage of his convictions to drive change. He was a quiet achiever; an entrepreneur who created Australia’s largest privately owned shipping company, Sea Swift.
In honour of Sid, sharing his vision and desire to drive change and innovation, Christine, Arran, Bradley, Jessie and their families have enabled us to continue to expand our world class research and support the next generation of talented young scientists.
QIMR Berghofer Brain Cancer Tissue and Culture Bank
Through an active and ongoing collaboration with the Royal Brisbane and Women’s Hospital (RBWH), neurosurgeon Dr Rosalind Jeffree and oncologists Dr Po Inglis and Dr Zarnie Lwin. The SFBC Laboratory has developed an extensive brain cancer tissue and culture bank. This resource has been critical in driving brain cancer discoveries in our laboratory and numerous laboratories worldwide. We have generated multiple primary brain cancer models from patient tumour tissue, these are used every day by scientists to make new discoveries and test the next generation of novel and effective therapies.
Brain Cancer Cell Line Resource: Q-Cell
Q-Cell aims to provide a source of high quality, well-characterized brain cancer cell lines for academic use. These resources are valuable to researchers seeking readily-usable, well-characterised, clinically-relevant, gold-standard models of GBM.
Resources are freely availability to the scientific community. Characterisation data can be accessed through the Q-Cell website https://www.qimrberghofer.edu.au/q-cell/.
For further information please contact Prof Bryan Day at email@example.com.
We couldn't do this without...
- Sid Faithfull and Christine Sadler.
- Cure Brain Cancer Foundation.
- Cancer Care Services: Royal Brisbane and Women’s Hospital Brisbane.
- The Kids Cancer Project.
- Royal Children's Hospital Foundation.
Day Lab Publications
- Stringer BW*, Day BW*, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhäuser C, Akgul S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis P, Jeffree RL, Johns TG, Boyd AW. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Scientific Reports. 2019 March 20. 9 (4902). IF = 4.122
- Akgül S, Patch AM, D'Souza RCJ, Mukhopadhyay P, Nones K, Kempe S, Kazakoss SH, Jeffree RL, Stringer BW, Pearson JV, Waddell N, Day BW. Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma. Cancers. Jan 2019; 11, 190. IF 5.326.
- Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce, ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs, AV, Bell CA, Jefree R, Rose S, Thurecht KJ, Bowd AW and Day BW. EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers. Dec 2018; 10 (12), 519. IF 5.326
- Lim YC, Quek H, Offenhäuser C, Lavin M, Boyd AW, Roberts T and Day BW. ATM Inhibition Prevents Interleukin-6 from Contributing to the Proliferation of Glioma Initiating Cells after Ionizing Radiation. Journal of Neuro-Oncology. Jan 2018; 138 (3), 509-518. IF 2.98
- Day BW, Stringer BW and Boyd AW. Eph Receptors as Therapeutic Targets in Glioblastoma. British Journal of Cancer. Invited Review 2014 Sep 23;111 (7):1255-61. IF 5.082
- Day BW, Stringer BW, Wilson J, et al. Glioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research. Cancers, 5(2), 357-371; April 4, 2013 doi:10.3390/cancers5020357
- Day BW, Stringer BW, Al-Ejeh F, et al. EphA3 Maintains Tumourigenicity and is a Therapeutic Target in Glioblastoma Multiforme. Cancer Cell 23, 238–248, February 11, 2013. IF 26.566
- Day BW, Stringer BW, Spanevello MD, et al. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. Neuro Oncology. 2011 Nov;13(11):1202-12. IF 6.2